Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -64.08 Billion KRW | -47.2% |
| 2022 | -43.53 Billion KRW | 38.0% |
| 2021 | -70.21 Billion KRW | 15.25% |
| 2020 | -82.85 Billion KRW | 22.59% |
| 2019 | -107.03 Billion KRW | -272.58% |
| 2018 | -28.72 Billion KRW | -342.28% |
| 2017 | -6.49 Billion KRW | -809.18% |
| 2016 | -714.45 Million KRW | -378.02% |
| 2015 | 256.98 Million KRW | 0.0% |
| 2013 | 265.71 Million KRW | 105.74% |
| 2012 | -4.63 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.35 Billion KRW | 85.29% |
| 2024 Q2 | -4.35 Billion KRW | 18.76% |
| 2023 Q4 | -36.43 Billion KRW | -340.04% |
| 2023 FY | -64.08 Billion KRW | -47.2% |
| 2023 Q1 | -10.81 Billion KRW | -3.1% |
| 2023 Q2 | -8.55 Billion KRW | 20.9% |
| 2023 Q3 | -8.27 Billion KRW | 3.26% |
| 2022 FY | -43.53 Billion KRW | 38.0% |
| 2022 Q2 | -9.64 Billion KRW | 23.66% |
| 2022 Q3 | -11.07 Billion KRW | -14.91% |
| 2022 Q1 | -12.63 Billion KRW | 42.51% |
| 2022 Q4 | -10.49 Billion KRW | 5.29% |
| 2021 Q3 | -4.31 Billion KRW | 81.45% |
| 2021 Q4 | -21.96 Billion KRW | -409.27% |
| 2021 FY | -70.21 Billion KRW | 15.25% |
| 2021 Q2 | -23.25 Billion KRW | -1417.08% |
| 2021 Q1 | -1.53 Billion KRW | -763.41% |
| 2020 FY | -82.85 Billion KRW | 22.59% |
| 2020 Q1 | -24.34 Billion KRW | 74.15% |
| 2020 Q2 | -25.18 Billion KRW | -3.45% |
| 2020 Q3 | -15.66 Billion KRW | 37.82% |
| 2020 Q4 | -177.56 Million KRW | 98.87% |
| 2019 Q2 | 13.63 Billion KRW | 181.43% |
| 2019 FY | -107.03 Billion KRW | -272.58% |
| 2019 Q1 | -16.74 Billion KRW | 2.56% |
| 2019 Q4 | -94.18 Billion KRW | -881.89% |
| 2019 Q3 | -9.59 Billion KRW | -170.34% |
| 2018 FY | -28.72 Billion KRW | -342.28% |
| 2018 Q3 | -5.93 Billion KRW | -185.92% |
| 2018 Q4 | -17.18 Billion KRW | -189.7% |
| 2018 Q2 | -2.07 Billion KRW | 6.13% |
| 2018 Q1 | -2.21 Billion KRW | 27.18% |
| 2017 Q3 | -942.67 Million KRW | 5.83% |
| 2017 FY | -6.49 Billion KRW | -809.18% |
| 2017 Q2 | -1 Billion KRW | 34.0% |
| 2017 Q1 | -1.51 Billion KRW | 0.0% |
| 2017 Q4 | -3.03 Billion KRW | -221.99% |
| 2016 FY | -714.45 Million KRW | -378.02% |
| 2015 FY | 256.98 Million KRW | 0.0% |
| 2014 Q1 | -922.16 Million KRW | -12.07% |
| 2014 Q3 | -673.33 Million KRW | -251.72% |
| 2014 Q2 | -191.43 Million KRW | 79.24% |
| 2013 FY | 265.71 Million KRW | 105.74% |
| 2013 Q3 | 1.09 Billion KRW | 95.01% |
| 2013 Q2 | 561 Million KRW | 199.05% |
| 2013 Q1 | -566.4 Million KRW | 86.5% |
| 2013 Q4 | -822.88 Million KRW | -175.22% |
| 2012 FY | -4.63 Billion KRW | 0.0% |
| 2012 Q4 | -4.19 Billion KRW | -541.95% |
| 2012 Q3 | 949.31 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 66.105% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -561.018% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 1472.123% |
| Bioneer Corporation | -10.58 Billion KRW | -505.349% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -2155.96% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 1197.405% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | -30.997% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -660.13% |
| Medy-Tox Inc. | 9.75 Billion KRW | 756.974% |
| Peptron, Inc. | -15.92 Billion KRW | -302.518% |
| Amicogen, Inc. | -23.28 Billion KRW | -175.189% |
| Genexine, Inc. | -66.87 Billion KRW | 4.165% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -2683.841% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 13.046% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -1800.739% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 183.72% |
| SillaJen, Inc. | -20.36 Billion KRW | -214.633% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 558.892% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | -235.512% |
| Genomictree Inc. | -8.75 Billion KRW | -631.934% |
| MedPacto, Inc. | -35.32 Billion KRW | -81.426% |
| D&D Pharmatech | 3.93 Billion KRW | 1729.172% |
| EASY BIO,Inc. | 15.54 Billion KRW | 512.309% |
| GI Innovation, Inc. | -55.49 Billion KRW | -15.484% |